Patents by Inventor Nicole Alexis Spiegelman

Nicole Alexis Spiegelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR MODULATING SCAP ACTIVITY
    Publication number: 20230374522
    Abstract: Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders, and/or conditions associated with SCAP activity such as nonalcoholic fatty liver disease (NAFLD), (NASH), dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and/or other SCAP-associated conditions, diseases, and/or disorders.
    Type: Application
    Filed: April 14, 2023
    Publication date: November 23, 2023
    Inventors: Bob Dale BROWN, Henryk T. DUDEK, Seongmoon CHEONG, Nicole Alexis SPIEGELMAN
  • COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION
    Publication number: 20230220398
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Application
    Filed: January 6, 2023
    Publication date: July 13, 2023
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression
    Patent number: 11578329
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: February 14, 2023
    Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION
    Publication number: 20220340912
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Application
    Filed: April 19, 2022
    Publication date: October 27, 2022
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen